"Protocol 17S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study)"

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: dementia | Parkinson's disease
  • Age: Between 40 - 85 Years
  • Gender: Male or Female

Inclusion Criteria
Have idiopathic PD per MDS criteria with at least 2 years of PD symptoms
Have dementia as defined by a decline in cognitive function, which in the opinion of the investigator has resulted in functional impairment
If on anti-parkinsonian agents, subjects must be on stable dosage for at least 4 weeks prior to Visit 2, and it is anticipated that no changes will be needed during the course of the study
If on medications affecting cognition (rivastigmine, galantamine, donepezil, memantine), subjects must be on stable dosage for at least 8 weeks prior to Visit 2 and expected to remain at a stable dosage during the course of the study
If on antidepressant medications, subjects must be on stable dosage for at least 8 weeks prior to Visit 2 and expected to remain on stable dosage during the course of the study
If on clozapine, quetiapine, and pimavanserin to address drug-induced or disease-related psychosis, subjects must be on a stable dosage for 4 weeks prior to Visit 2 and expected to remain at a stable dosage during the course of the study
If on antihypertensive medications, subjects must be on stable dosage for at least 3 months prior to Visit 1
Are able to swallow capsules
All subjects must have a reliable caregiver who is in frequency contact with the subject (defined as at least 10 hours per week) and will accompany the subject to Visit 1, Visit 2, Visit 4, Visit 8, Visit 11 and Visit 801
Agree not to post any personal medical data related to the study or information related to the study on any website or social media (eg, Facebook, Twitter, LinkedIn, Google+, etc.)
Exclusion Criteria
Are WOCBP
Have significant central nervous system disease, other than PD, that may affect cognition or the ability to complete the study, including but not limited to other dementias (eg, Alzheimer's disease [AD})
Have a history in the last 6 months of transient ischemic attacks or ischemic stroke
Have a history of intra-cerebral hemorrhage due to hypertension
Have a history of hypertensive encephalopathy
Have atypical or secondary parkinsonism due to drugs (eg, antipsychotics) or disease (such as progressive supranuclear palsy, essential tremor, multiple system atrophy [eg, striatonigral degeneration, olivopontocerebellar atrophy], or postencephalitic parkinsonism)
Have a current implantable intracranial stimulator or history of intracranial ablation surgery (eg, subthalamic, globus pallidus-internal segment)
Have a current or any previous diagnosis of bipolar disorder, schizophrenia, or other primary psychotic disorder
Have poorly controlled psychosis (hallucinations or delusions) that in the opinion of the investigator would interfere with the subject's ability to be compliant with the study protocol
Have any other psychiatric disorder that, in the judgment of the investigator, would interfere with compliance with the study protocol
Have a serious or unstable medical illness, other than idiopathic PD, including cardiovascular, hepatic, respiratory, hematologic, endocrinologic, neurologic, or renal disease, or clinically significant laboratory or electrocardiogram (ECG) abnormality as determined by the investigator.
Subjects with acute liver disease
Have used antipsychotic medications, with the exception of clozapine, quetiapine, pimavanserin in the 6 months prior to screening (Visit 1) and at any time during the course of the study
Have used trihexphenidyl and benztropien in the 4 weeks prior to screening (Visit 1) and at any time during the course of the study
Have a motor conditions for which the antiparkinsonian teratment is expected to change during the course of the study, as well as unpredictable motor fluctuations that in the investigator's opinion would interfere with conducting assessments
Are currently taking any medications or food, herbal or dietary supplements that are inhibitors (eg, ketoconazole, grapefruit juice), or strong/moderate inducers of cytochrome P450 3A4 (CP3A4) (eg, rifampicin)
Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
Have participated, within the last 3 months, in a clinical study involving an interventional product or device
Have previously been exposed to LY3154207

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176